MANY MINDEDOctapharma commits $1.5bn to a US plasma-medicine plant
1,500 jobs · a job the company says the Rock Hill plant will create, with operations starting mid-2030s · proposedmeasured · Manufacturing Dive, 2026-08-03 — Source states "The project is expected to bring 1,500 jobs to South Carolina". Expected, not filled - state is proposed and operations are scheduled for the mid-2030s. Annual null: a headcount is not
Octapharma, the Swiss plasma products group, will invest $1.5 billion in its first United States manufacturing facility, on a 50-acre campus at Palmetto Research Park in Rock Hill, South Carolina. The plant will make plasma-derived medicines and is expected to employ about 1,500 people. Operations are scheduled to begin in the mid-2030s. South Carolina's economic development council approved job development credits and awarded York County a $65 million grant for site preparation, construction and infrastructure.
The company declined to state production capacity, saying the project is still in planning and that it will know more once construction begins and equipment procurement starts.
Plasma-derived medicines — immunoglobulins, clotting factors, albumin — sit in an awkward place on the road to free. They are made from donated human plasma, so the input does not follow a manufacturing cost curve the way a synthesised drug does; supply is set by how many people donate and how much fractionation capacity exists to process it. Shortages in this category are chronic and they show up as rationing rather than as price. New fractionation capacity is one of the few things that genuinely moves the constraint.
The honest caveat is the clock. Mid-2030s means this changes nothing for a decade, and without a stated capacity there is no way to size the effect even then. It is a commitment with a site and a grant behind it, which is more than an intention, and considerably less than a supply.
Source: Manufacturing Dive